CONTEXT: Mouse studies suggest that adropin, a peptide hormone, is required for metabolic homeostasis and prevention of obesity-associated insulin resistance. Whether obesity and insulin resistance are associated with low plasma adropin levels in humans is not known. OBJECTIVES: Our objective was to investigate the hypothesis that obesity and indicators of insulin resistance are associated with low adropin levels and determine whether weight loss regulates adropin levels. DESIGN AND PARTICIPANTS: Plasma was obtained from 85 female [age 21-67 yr, body mass index (BMI) 19.4-71.5 kg/m2] and 45 male (age 18-70 yr, BMI 19.1-62.6 kg/m2) volunteers for other clinical studies. The impact of Roux-en-Y gastric bypass was investigated in 19 obese females (BMI 37-65 kg/m2) using samples collected at baseline and 1-12 months after surgery. RESULTS: Adropin levels correlate negatively with BMI (r=-0.335, P<0.001) and age (r=-0.263, P=0.003). Age-adjusted adropin levels are higher in males [4.1 ng/ml; 95% confidence interval (CI)=3.6-4.6 ng/ml] than females (3.0 ng/ml; 95% CI=2.6-3.4 ng/ml) (P=0.001). In all subjects, lower age-adjusted adropin levels were observed in overweight (3.3 ng/ml; 95% CI=2.8-3.8 ng/ml, P=0.033) and obese (2.7 ng/ml; 95% CI=2.1-3.3 ng/ml, P=0.001) compared with healthy-weight subjects (4.1 ng/ml; 95% CI=3.6-4.5 ng/ml). This effect was gender specific (weight category×gender, P<0.001) and was observed in males only. Aging and diagnosis with two or more metabolic syndrome risk factors was associated with low adropin levels, irrespective of sex. Adropin concentrations increased after Roux-en-Y gastric bypass, peaking 3 months after surgery (P<0.01). CONCLUSIONS: Although males exhibit higher adropin levels that are reduced by obesity, aging and markers of insulin resistance are associated with low plasma adropin irrespective of sex.
CONTEXT: Mouse studies suggest that adropin, a peptide hormone, is required for metabolic homeostasis and prevention of obesity-associated insulin resistance. Whether obesity and insulin resistance are associated with low plasma adropin levels in humans is not known. OBJECTIVES: Our objective was to investigate the hypothesis that obesity and indicators of insulin resistance are associated with low adropin levels and determine whether weight loss regulates adropin levels. DESIGN AND PARTICIPANTS: Plasma was obtained from 85 female [age 21-67 yr, body mass index (BMI) 19.4-71.5 kg/m2] and 45 male (age 18-70 yr, BMI 19.1-62.6 kg/m2) volunteers for other clinical studies. The impact of Roux-en-Y gastric bypass was investigated in 19 obese females (BMI 37-65 kg/m2) using samples collected at baseline and 1-12 months after surgery. RESULTS:Adropin levels correlate negatively with BMI (r=-0.335, P<0.001) and age (r=-0.263, P=0.003). Age-adjusted adropin levels are higher in males [4.1 ng/ml; 95% confidence interval (CI)=3.6-4.6 ng/ml] than females (3.0 ng/ml; 95% CI=2.6-3.4 ng/ml) (P=0.001). In all subjects, lower age-adjusted adropin levels were observed in overweight (3.3 ng/ml; 95% CI=2.8-3.8 ng/ml, P=0.033) and obese (2.7 ng/ml; 95% CI=2.1-3.3 ng/ml, P=0.001) compared with healthy-weight subjects (4.1 ng/ml; 95% CI=3.6-4.5 ng/ml). This effect was gender specific (weight category×gender, P<0.001) and was observed in males only. Aging and diagnosis with two or more metabolic syndrome risk factors was associated with low adropin levels, irrespective of sex. Adropin concentrations increased after Roux-en-Y gastric bypass, peaking 3 months after surgery (P<0.01). CONCLUSIONS: Although males exhibit higher adropin levels that are reduced by obesity, aging and markers of insulin resistance are associated with low plasma adropin irrespective of sex.
Authors: Saul Genuth; K G M M Alberti; Peter Bennett; John Buse; Ralph Defronzo; Richard Kahn; John Kitzmiller; William C Knowler; Harold Lebovitz; Ake Lernmark; David Nathan; Jerry Palmer; Robert Rizza; Christopher Saudek; Jonathan Shaw; Michael Steffes; Michael Stern; Jaako Tuomilehto; Paul Zimmet Journal: Diabetes Care Date: 2003-11 Impact factor: 19.112
Authors: M M Swarbrick; I T Austrheim-Smith; K L Stanhope; M D Van Loan; M R Ali; B M Wolfe; P J Havel Journal: Diabetologia Date: 2006-09-21 Impact factor: 10.122
Authors: K Ganesh Kumar; Jingying Zhang; Su Gao; Jari Rossi; Owen P McGuinness; Heather H Halem; Michael D Culler; Randall L Mynatt; Andrew A Butler Journal: Obesity (Silver Spring) Date: 2012-02-09 Impact factor: 5.002
Authors: Kitt Falk Petersen; Sylvie Dufour; David B Savage; Stefan Bilz; Gina Solomon; Shin Yonemitsu; Gary W Cline; Douglas Befroy; Laura Zemany; Barbara B Kahn; Xenophon Papademetris; Douglas L Rothman; Gerald I Shulman Journal: Proc Natl Acad Sci U S A Date: 2007-07-18 Impact factor: 11.205
Authors: M M Swarbrick; K L Stanhope; I T Austrheim-Smith; M D Van Loan; M R Ali; B M Wolfe; P J Havel Journal: Diabetologia Date: 2008-08-15 Impact factor: 10.122
Authors: Kimber L Stanhope; Steven C Griffen; Brandi R Bair; Michael M Swarbrick; Nancy L Keim; Peter J Havel Journal: Am J Clin Nutr Date: 2008-05 Impact factor: 7.045
Authors: Subhashis Banerjee; Sarbani Ghoshal; Joseph R Stevens; Kyle S McCommis; Su Gao; Mauricio Castro-Sepulveda; Maria L Mizgier; Clemence Girardet; K Ganesh Kumar; Jose E Galgani; Michael L Niehoff; Susan A Farr; Jinsong Zhang; Andrew A Butler Journal: J Biol Chem Date: 2020-07-29 Impact factor: 5.157
Authors: Su Gao; Sarbani Ghoshal; Liyan Zhang; Joseph R Stevens; Kyle S McCommis; Brian N Finck; Gary D Lopaschuk; Andrew A Butler Journal: J Biol Chem Date: 2019-07-19 Impact factor: 5.157
Authors: Andrew A Butler; James L Graham; Kimber L Stanhope; So Wong; Sarah King; Andrew A Bremer; Ronald M Krauss; James Hamilton; Peter J Havel Journal: J Lipid Res Date: 2020-01-09 Impact factor: 5.922
Authors: Joseph R Stevens; Monica L Kearney; Marie-Pierre St-Onge; Kimber L Stanhope; Peter J Havel; Jill A Kanaley; John P Thyfault; Edward P Weiss; Andrew A Butler Journal: Obesity (Silver Spring) Date: 2016-08 Impact factor: 5.002